QT Monitoring Impacts More Than Just Cardiac Health

The Benefits of QT Monitoring

QT monitoring is pivotal for sponsors, enhancing more than just safety; it helps streamline development pipelines through early-phase comprehensive safety assessments. This contributes to reducing time to market entry and easing regulatory processes, while insights gained allow for greater opportunities in treatment personalization. This enables sponsors to refine patient selection for future trial phases, and improve the prospects of trial success.

Key Applications of QT Monitoring

The broad utility of QT monitoring highlights its essential role across various therapeutic areas. Here are some key applications:

Safety Assessments: QT monitoring can ensure that the drug under investigation does not have a detrimental effect on cardiac repolarization, which can lead to arrhythmias. For instance, in oncology, it can be used to identify early cardiac risks associated with new treatments, and in psychiatry to develop safer medications with reduced cardiovascular risk profiles.

Regulatory Compliance: Regulatory agencies like the FDA and EMA recommend QT interval assessment for most new drugs as part of their safety evaluation process. Demonstrating that a drug does not significantly affect the QT interval is often a requirement for approval. The guidance states that "Drugs are expected to receive a clinical electrocardiographic evaluation beginning early in clinical development, typically including a single trial dedicated to evaluating their effect on cardiac repolarization ('thorough QT/QTc study')".¹

Drug Differentiation: Demonstrating a neutral or lesser impact on the QT interval for drugs in the same therapeutic class can be a distinguishing safety feature. When comparing the effectiveness of a new drug against existing treatments or a placebo, as often is done with antipsychotic medications, a favorable QT profile can serve as a key differentiator—especially in competitive markets.

Dose Finding: QT monitoring helps in identifying the safe dose ranges of a drug. For example, researchers can examine how different doses of opioids impact the QT interval to establish optimal dosing regimens that minimize the risk of cardiac arrhythmias while maximizing pain relief. By determining the dose-response relationship with respect to QT prolongation, researchers can optimize dosing regimens to minimize risk.

Patient Selection and Risk Management: By identifying patient populations that may be more susceptible to QT prolongation (e.g., patients with existing QT conditions or those taking other QT-prolonging medications), sponsors can design trials that are safer and more targeted. This personalized approach can enhance the trial's success rate and patient safety.

New Technology that Broadens the Scope of QT Monitoring

Given the clear benefits of QT monitoring in enhancing drug development and trial safety, it's natural to wonder why its application isn’t more widespread across diverse drug trials. The answer often lies in the challenges posed by traditional 12-lead ECGs, which require on-site clinic visits and bulky equipment, placing physical burdens on patients.

Recent innovations, however, are breaking down these barriers, allowing for more precise and flexible QT monitoring solutions. For example, AliveCor has launched Kardia 12L the world’s first AI-powered handheld 12-lead ECG system with a unique single-cable design for use by physicians, providing an alternative to traditional 12-lead systems. However, for decentralized or hybrid trials, where ease of use and remote QT monitoring are key, the KardiaMobile® 6L serves as a vital complement.

With KardiaMobile® 6L, trials become:

• More Accurate with Comprehensive Data: The FDA-cleared KardiaMobile 6L enables precise remote cardiac monitoring and QT interval measurements*, crucial for comprehensive safety monitoring in clinical trials. It facilitates accurate assessments of conditions like atrial fibrillation (AFib), bradycardia, tachycardia, and other significant cardiac rhythms, enhancing the reliability and clinical relevance of the data.
• Decentralized Trials: KardiaMobile 6L supports remote ECG recording, which not only enhances the accessibility of QT monitoring but also enables broader participation in decentralized clinical trials. This integration reduces logistical challenges with remote-friendly monitoring , allowing researchers to conduct trials with greater flexibility and efficiency.
• Fast and Efficient: Real-time data provides clinicians with immediate access to high-quality measurements, streamlining the clinical trial process and improving the efficiency of data analysis.
• Patient-Centric: The device's user-friendly self-administration and remote capabilities empower patients to participate more actively in their clinical trials, which can lead to higher engagement and better compliance.
• Inclusive: With remote-friendly and efficient data collection, KardiaMobile 6L allows more inclusive study designs by enabling participation from location centric and geographical locations.

What Does More QT Monitoring Mean for the Future?

A study on digital technologies in clinical trials even suggests that, "The density and continuous nature of the data collected, particularly during early drug development, could support earlier detection of adverse events and allow for more optimized dose titration outside of office visits. Furthermore, continuous data output creates an opportunity for the development of novel endpoints that were previously inaccessible via traditional clinical trials."²

With KardiaMobile 6L, sponsors can reliably monitor QT intervals at every trial stage—no matter the drug.

With greater access to QT data and integration of advanced monitoring technologies can come greater trial successes benefitting sponsors, participants, and ultimately, patients.

Ready to harness the benefits of QT monitoring in your clinical trials? Discover how KardiaMobile 6L can innovate your approach today.

Learn More

Resources:

https://www.cancertreatmentreviews.com/article/S0305-7372(17)30201-3/pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946151/
https://karger.com/mpp/article/27/5/401/204443/Opioids-and-Cardiac-Arrhythmia-A-Literature-Review
https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm
https://www.fda.gov/media/71379/download

*QT measurements made using EK12 ECG algorithm.